New Long-Acting HIV shot enters human safety trials

NCT ID NCT06310551

First seen Mar 18, 2026 · Last updated May 09, 2026 · Updated 6 times

Summary

This study tests a new long-acting injectable drug called VH4524184 in healthy adults to see if it is safe and well-tolerated. The goal is to find a dose that could be used as a future HIV treatment, given as a shot instead of daily pills. About 268 healthy volunteers aged 18 to 55 will receive either the drug or a placebo and be monitored for side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Lenexa, Kansas, 66219, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    San Antonio, Texas, 78209, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    Salt Lake City, Utah, 84124, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.